A series of inhibitors of Autotaxin (ATX) has been developed using the binding mode of known inhibitor, PF-8380, as a template. Replacement of the benzoxazolone with a triazole zinc-binding motif reduced crystallinity and improved solubility relative to PF-8380. Modification of the linker region removed hERG activity and led to compound 12 - a selective, high affinity, orally-bioavailable inhibitor of ATX. Compound 12 concentration-dependently inhibits autotaxin and formation of LPA in vivo, as shown in pharmacokinetic-pharmacodynamic experiments.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bmcl.2018.05.030 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Myeloid-specific deletion of autotaxin inhibits rheumatoid arthritis and osteoclastogenesis.
Front Immunol
January 2025
Department of Pharmacy, College of Pharmacy, Pusan National University, Busan, Republic of Korea.
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint swelling, pain, and bone remodeling. We previously reported that autotaxin (ATX) deficiency disrupts lipid rafts in macrophages. Lipid raft disruption results in the dysregulation of RANK signaling, which is crucial for osteoclastogenesis and the pathogenesis of RA.
View Article and Find Full Text PDFDesign, synthesis and evaluation of 3-(2-(substituted benzyloxy)benzylidene) pyrrolidine-2,5-dione derivatives for novel ATX inhibitor.
Bioorg Med Chem Lett
December 2024
Data Convergence Drug Research Center, Korea Research Institute of Chemical Technology, Yuseong-gu, Daejeon 34114, Republic of Korea; Department of Medicinal Chemistry and Pharmacology, KRICT School, University of Science and Technology, Yuseong-gu, Daejeon 34113, Republic of Korea. Electronic address:
Article Synopsis
- Autotaxin (ATX) is being targeted for new liver disease treatments, and drug candidates were identified through high-throughput screening methods.
- Researchers synthesized a small molecule called KR-40795, designed to inhibit ATX's activity by binding to specific regions of the enzyme.
- KR-40795 effectively reduced collagen formation and lipid accumulation in liver cells, showcasing its potential to treat liver conditions like fibrosis and steatosis.
Serum Autotaxin Levels Predict Liver-Related Events in Patients With Primary Biliary Cholangitis: A Long-Term Multicenter Observational Study.
Clin Transl Gastroenterol
December 2024
Department of Medicine, Division of Gastroenterology and Hepatology, Shinshu University School of Medicine, Matsumoto, Japan.
Article Synopsis
- A study explored the potential of serum autotaxin (ATX) as a predictor for liver-related events (LRE) in patients with primary biliary cholangitis (PBC).
- During a median follow-up of 9.7 years of 190 untreated patients, those with ATX levels ≥1.086 mg/L experienced significantly more LRE compared to those with lower levels (33.3% vs 3.6%).
- The research suggests that ATX is a strong independent predictor for LRE, outperforming existing markers, and aligns with findings from a separate validation cohort of PBC patients.
Comparative transcriptomic analysis validates iPSC derived in-vitro progressive fibrosis model as a screening tool for drug discovery and development in systemic sclerosis.
Sci Rep
October 2024
Department of Immunology and Respiratory Disease Research, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA.
Article Synopsis
- - Systemic sclerosis (SSc) is an autoimmune disease that leads to issues like blood vessel dysfunction, immune system problems, and widespread tissue scarring, but studying it has been tough due to a lack of relevant research models.
- - Researchers created an innovative in-vitro model using induced pluripotent stem cell-derived mesenchymal cells (iSCAR) to mimic the scarring seen in SSc, allowing for detailed investigation of gene expression tied to scarring at different stages.
- - The study confirms that the iSCAR model can be effectively used to test antifibrotic drugs, demonstrating responses to different compounds and revealing significant insights into the genes involved in both early and late stages of fibrosis.
Bronchopulmonary dysplasia demonstrates dysregulated autotaxin/lysophosphatidic acid signaling in a neonatal mouse model.
Pediatr Res
October 2024
Department of Pediatrics, School of Medicine, Case Western Reserve University, Cleveland, OH, USA.
Background: Bronchopulmonary dysplasia (BPD) is a chronic lung disease affecting premature infants who require oxygen supplementation and ventilator therapy to support their underdeveloped lungs. Autotaxin (ATX), an enzyme that generates the bioactive phospholipid lysophosphatidic acid (LPA), which acts via G-protein coupled receptors, has been implicated in numerous pulmonary diseases. In this study, we explored the pathophysiological role of the ATX/LPA signaling pathway in BPD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!